Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Rhea-AI Summary

Cara Therapeutics (CARA) announced a conference call on February 25, 2021, at 4:30 p.m. ET, to discuss its fourth quarter and full year 2020 financial results. Investors can join by dialing (855) 445-2816 (domestic) or (484) 756-4300 (international). The call will also be accessible via a live audio webcast on the company's website. Notably, Cara is advancing KORSUVA™ (difelikefalin) for pruritus treatment, having submitted a New Drug Application (NDA) to the FDA, requesting Priority Review, which could expedite the review process.

Positive

• KORSUVA™ Injection received Breakthrough Therapy Designation from the FDA.
• Cara has submitted an NDA for KORSUVA™ and requested Priority Review, potentially shortening the review timeline.

Negative

• None.

STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021, at 4:30 p.m. ET to report fourth quarter and full year 2020 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 6676157. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KORSUVA™ Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients. KORSUVA Injection received Breakthrough Therapy Designation from the FDA for this indication. Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process. Oral KORSUVA has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

FAQ

When is Cara Therapeutics' earnings call for Q4 2020?

Cara Therapeutics will host its earnings call on February 25, 2021, at 4:30 p.m. ET.

What is the status of KORSUVA™ Injection from Cara Therapeutics?

KORSUVA™ Injection has received Breakthrough Therapy Designation and is under an NDA review by the FDA.

How can I access the conference call for Cara Therapeutics?

You can access the conference call by dialing (855) 445-2816 domestically or (484) 756-4300 internationally, and refer to conference ID 6676157.

What are the future prospects for KORSUVA™ from Cara Therapeutics?

KORSUVA™ is currently in clinical trials and has shown promise in treating pruritus in various patient populations.